Clinical pharmacology

Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board

Tuesday, March 2, 2021 - 2:00pm

Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board.

Key Points: 
  • Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board.
  • Craig is a recognized visionary leader who has spent his career dedicated to transforming some of the most challenging issues in clinical research through new innovations.
  • The core mission of DTRA is making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
  • We are honored to have Craig as the chair of our Industry Advisory Board.

Global Virtual Clinical Trials Market 2020-2027 - Fear Among Clinical Investigators for COVID-19 Presents Opportunities

Monday, March 1, 2021 - 4:45pm

Virtual Clinical Trials (VCT) are a new method of directing clinical trials which is inclusive of web platforms (informed consent, recruitment, adverse reactions, counseling and measurement of endpoints) and taking advantage of technology such as monitoring devices, apps and others.

Key Points: 
  • Virtual Clinical Trials (VCT) are a new method of directing clinical trials which is inclusive of web platforms (informed consent, recruitment, adverse reactions, counseling and measurement of endpoints) and taking advantage of technology such as monitoring devices, apps and others.
  • The growth of virtual clinical trials is mainly owing to the advantages offered by these trials in place of traditional clinical trials.
  • Additionally, COVID-19 pandemic has led to upsurge virtual clinical trials given the trials need to be conducted digitally.
  • Players in the market are strategizing on developing new virtual clinical trial technology to cope up with the augmenting healthcare industry and thereby, establish their market place.

Global Connected Drug Delivery Devices (Bluetooth, NFC, Other) Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Monday, March 1, 2021 - 3:13pm

The "Connected Drug Delivery Devices Market Size, Share & Trends Analysis Report by Technology (Bluetooth, NFC), by Product (Connected Sensors, Integrated Connected Devices), by End User, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Connected Drug Delivery Devices Market Size, Share & Trends Analysis Report by Technology (Bluetooth, NFC), by Product (Connected Sensors, Integrated Connected Devices), by End User, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Connected drug delivery devices help physicians to monitor the compliance of patients to the therapy prescribed by them as well as to modify the treatment of the patient treatment as required.
  • A growing number of initiatives to create awareness regarding the complexities caused by overdosage or underdosage of medicines is expected to promote the adoption of connected drug delivery devices.
  • Chapter 3 Global Connected Drug Delivery Devices Market Variables, Trends & Scope
    3.3 Global Connected Drug Delivery Devices Market- SWOT Analysis, by Factor (Political & legal, Economic and Technological)
    Chapter 4 Connected Drug Delivery Devices Market: Competitive Analysis

Global Medication Adherence Markets (2021 to 2025) - Key Market Drivers and Restraints

Friday, February 26, 2021 - 9:45pm

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Medication Adherence: Systems, Technologies and Global Markets 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Medication Adherence: Systems, Technologies and Global Markets 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report is an analytical business tool whose primary purpose is to provide a thorough evaluation of the global market for medication adherence.
  • Overall, medication adherence systems offer improved drug adherence, real-time data monitoring, logical calculations and network communication.
  • Medication adherence systems can be categorized into two major segments: hardware-based medication adherence systems and software-based internet applications (apps).

Dr. Reddy's Recalls Prescription Drug Blister Packages Due to Risk of Poisoning

Thursday, February 25, 2021 - 9:49pm

The prescription medications were distributed by third party wholesalers to retail pharmacies and could have been dispensed to consumers.

Key Points: 
  • The prescription medications were distributed by third party wholesalers to retail pharmacies and could have been dispensed to consumers.
  • The packaging of the products is not child resistant and can pose a risk of poisoning if the contents are swallowed by young children.
  • Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
  • This recall involves blister packages of prescription medications.

Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

Thursday, February 25, 2021 - 9:05pm

To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers.

Key Points: 
  • To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers.
  • Three patients have been enrolled in the fourth dose cohort (10mg/kg) of the dose escalation portion of the trial.
  • Research and development expenses for the year ended December 31, 2020 were $62.0 million, including non-cash share-based compensation expense of $5.9 million.
  • General and administrative expenses for the year ended December 31, 2020 were $26.8 million, including non-cash share-based compensation expense of $6.6 million.

Q2i's OARS software application moves to Phase II of National Institute of Health (NIH) clinical trial which will evaluate the application's efficacy in improving Opioid Use Disorder treatment

Thursday, February 25, 2021 - 7:33pm

This comes after a successful Phase I trial and with over 1000 patients it's the largest trial of its kind in the country.

Key Points: 
  • This comes after a successful Phase I trial and with over 1000 patients it's the largest trial of its kind in the country.
  • OARS is designed to increase patient engagement, program adherence, and MAT program availability as well as increasing treatment retention.
  • UCLA is Q2i's academic partner for this project with Dr. Steven Shoptaw leading the research team that is evaluating the OARS software application.
  • Dr. Shoptaw said, "The availability and access gap for OUD patients seeking treatment is a real issue that needs addressing.

Matrix Medical Network Announces Newly Defined Lines of Business with a Strategic Focus on Bringing Expert Care to Individuals Where They Live and Work

Thursday, February 25, 2021 - 5:43pm

Today's announcement represents a long-term strategic roadmap for Matrix recognizing new and unique health and safety needs in 2021 and beyond.

Key Points: 
  • Today's announcement represents a long-term strategic roadmap for Matrix recognizing new and unique health and safety needs in 2021 and beyond.
  • The newly defined business units are Clinical Care, Clinical Solutions, Clinical Trials and Clinical Labs.
  • Matrix Medical Network has provided expert care and health services to millions of at-risk individuals where they live and work for more than 20 years.
  • *Matrix Medical Network is the registered trademark of Community Care Health Network, LLC.

Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial

Thursday, February 25, 2021 - 2:30pm

CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Companys landmark ONWARD pivotal Phase 3 clinical trial.

Key Points: 
  • CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Companys landmark ONWARD pivotal Phase 3 clinical trial.
  • We are pleased to have achieved this important enrollment milestone in our ONWARD pivotal Phase 3 clinical trial, stated Schuyler Vinzant, Adials Vice President of Development.
  • We have a high degree of confidence that ONWARD will be fully enrolled this summer.
  • Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled.

Global $71.43 Billion Telepharmacy Market to 2027 - ResearchAndMarkets.com

Thursday, February 25, 2021 - 2:33pm

Certain services involved in telepharmacy includes patient counselling, drug therapy monitoring, refill authorization and prior authorization needed for the prescription drugs.

Key Points: 
  • Certain services involved in telepharmacy includes patient counselling, drug therapy monitoring, refill authorization and prior authorization needed for the prescription drugs.
  • Other telepharmacy services comprises of monitoring the formulary compliance through the deployment of videoconferencing or teleconferencing.
  • The prominent factors favoring the global market growth include advancement in technology, substantial investments in telepharmacy and rise in the prevalence of diseases.
  • Players in the market are focusing on strategic partnership with other key companies to strengthen their market position across the globe.